Cell culture bioreactors
Cell Culture

We work with most cell lines used for manufacturing monoclonal antibodies and recombinant proteins, including CHO, NS/0, BHK, 293 as well as murine hybridomas, and all selection systems used with these lines.
We have also worked with several different selection systems such as dhfr / methotrexate CHO, mycophenolic acid/xanthine, and G418 systems. Our experience includes attached or surface dependent as well as suspension culture types.

For more information, click here.



For the latest GBI news click here.
For additional information, please contact us:
954-327-9656
800-814-8600 Ext 156

info@GoodwinBio.com

Who We Are

A Passion For the Patient

While many CMOs entered the biotechnology CMO market as a for-profit organization, GBI has a different heritage. Born from the Goodwin Institute for Cancer Research, one of the first manifestations was the value of blending scientific expertise with a passion for the patient. This fueled a number of promising advancements in the treatment of cancer at the bench top level. The rigors of scaling up with therapeutics to test that promise, coupled with governmental rules and regulations, fueled an important business decision in 1992, Goodwin Biotechnology, Inc. was born.



Since then, we've maintained one key attribute, a focus on the patient. That's what motivates us to do a great job on your project.

One-Stop Shopping

In the biologics CMO niche, GBI was the first to engineer the concept of "full integration", which enables us to work with our clients from Proof of Concept through the manufacture of pre-clinical and clinical trial products. It a process we termed "GMPnization". In other words, we begin with the end in mind. Regardless of whether you are working on a Translational Medicine project or need a partner to manufacture material for clinical studies, we employ cGMP quality from the initial production step of developing the genetically engineered "production" cell line all the way through scale up and vialing of the final biopharmaceutical product.

GBI has an enviable reputation for regulatory compliance and, throughout our history, we have provided superior service for our clients that not only meets, but exceeds their expectations. Towards that end, we have completed nearly 400 projects for more than 100 U.S. and international clients, and assisted in the filing INDs for client products.

Security in an Unstable World

In 2004, GBI was acquired by Wallace Pharmaceuticals Pvt. Ltd. based in India. For over 40 years, Wallace Pharma has been building a visible and growing branded generic formulations and biotechnology presence across markets in the Americas, Asia and Africa. Their mission is to be a global leader in affordable niche healthcare solutions. Available to anyone, anywhere in the world.

HOME  |  SITEMAP   |   CONTACT US

© Copyright 2013 | Goodwin Biotechnology, Inc.